Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 127

1.

The chimeric protein domain III-capsid of dengue virus serotype 2 (DEN-2) successfully boosts neutralizing antibodies generated in monkeys upon infection with DEN-2.

Valdés I, Gil L, Romero Y, Castro J, Puente P, Lazo L, Marcos E, Guzmán MG, Guillén G, Hermida L.

Clin Vaccine Immunol. 2011 Mar;18(3):455-9. doi: 10.1128/CVI.00382-10. Epub 2011 Jan 5.

2.

Heterologous prime-boost strategy in non-human primates combining the infective dengue virus and a recombinant protein in a formulation suitable for human use.

Valdés I, Hermida L, Gil L, Lazo L, Castro J, Martín J, Bernardo L, López C, Niebla O, Menéndez T, Romero Y, Sánchez J, Guzmán MG, Guillén G.

Int J Infect Dis. 2010 May;14(5):e377-83. doi: 10.1016/j.ijid.2009.06.017. Epub 2009 Sep 20.

3.

Induction of protective immunity against Dengue virus type 2: comparison of candidate live attenuated and recombinant vaccines.

Velzing J, Groen J, Drouet MT, van Amerongen G, Copra C, Osterhaus AD, Deubel V.

Vaccine. 1999 Mar 17;17(11-12):1312-20.

PMID:
10195766
5.

A novel tetravalent formulation combining the four aggregated domain III-capsid proteins from dengue viruses induces a functional immune response in mice and monkeys.

Suzarte E, Gil L, Valdés I, Marcos E, Lazo L, Izquierdo A, García A, López L, Álvarez M, Pérez Y, Castro J, Romero Y, Guzmán MG, Guillén G, Hermida L.

Int Immunol. 2015 Aug;27(8):367-79. doi: 10.1093/intimm/dxv011. Epub 2015 Mar 20.

PMID:
25795768
6.

Virus-like particles displaying envelope domain III of dengue virus type 2 induce virus-specific antibody response in mice.

Arora U, Tyagi P, Swaminathan S, Khanna N.

Vaccine. 2013 Jan 30;31(6):873-8. doi: 10.1016/j.vaccine.2012.12.016. Epub 2012 Dec 20.

PMID:
23261049
7.

A consensus envelope protein domain III can induce neutralizing antibody responses against serotype 2 of dengue virus in non-human primates.

Chen HW, Liu SJ, Li YS, Liu HH, Tsai JP, Chiang CY, Chen MY, Hwang CS, Huang CC, Hu HM, Chung HH, Wu SH, Chong P, Leng CH, Pan CH.

Arch Virol. 2013 Jul;158(7):1523-31. doi: 10.1007/s00705-013-1639-1. Epub 2013 Mar 1.

PMID:
23456422
8.
9.

Broad neutralization of wild-type dengue virus isolates following immunization in monkeys with a tetravalent dengue vaccine based on chimeric yellow fever 17D/dengue viruses.

Barban V, Munoz-Jordan JL, Santiago GA, Mantel N, Girerd Y, Gulia S, Claude JB, Lang J.

Virology. 2012 Aug 1;429(2):91-8. doi: 10.1016/j.virol.2012.03.007. Epub 2012 Apr 25.

10.

DENV-2 subunit proteins fused to CR2 receptor-binding domain (P28)-induces specific and neutralizing antibodies to the Dengue virus in mice.

García-Machorro J, López-González M, Barrios-Rojas O, Fernández-Pomares C, Sandoval-Montes C, Santos-Argumedo L, Villegas-Sepúlveda N, Gutiérrez-Castañeda B, Cedillo-Barrón L.

Hum Vaccin Immunother. 2013 Nov;9(11):2326-35. Epub 2013 Jul 23.

11.

Dengue-1 envelope protein domain III along with PELC and CpG oligodeoxynucleotides synergistically enhances immune responses.

Chiang CY, Huang MH, Hsieh CH, Chen MY, Liu HH, Tsai JP, Li YS, Chang CY, Liu SJ, Chong P, Leng CH, Chen HW.

PLoS Negl Trop Dis. 2012;6(5):e1645. doi: 10.1371/journal.pntd.0001645. Epub 2012 May 15.

12.

Development of a recombinant tetravalent dengue virus vaccine: immunogenicity and efficacy studies in mice and monkeys.

Clements DE, Coller BA, Lieberman MM, Ogata S, Wang G, Harada KE, Putnak JR, Ivy JM, McDonell M, Bignami GS, Peters ID, Leung J, Weeks-Levy C, Nakano ET, Humphreys T.

Vaccine. 2010 Mar 24;28(15):2705-15. doi: 10.1016/j.vaccine.2010.01.022. Epub 2010 Jan 22.

13.

Evaluation in mice of the immunogenicity and protective efficacy of a tetravalent subunit vaccine candidate against dengue virus.

Lazo L, Izquierdo A, Suzarte E, Gil L, Valdés I, Marcos E, Álvarez M, Romero Y, Guzmán MG, Guillén G, Hermida Cruz L.

Microbiol Immunol. 2014 Apr;58(4):219-26. doi: 10.1111/1348-0421.12140.

14.
15.

A tetravalent dengue vaccine containing a mix of domain III-P64k and domain III-capsid proteins induces a protective response in mice.

Izquierdo A, García A, Lazo L, Gil L, Marcos E, Alvarez M, Valdés I, Hermida L, Guillén G, Guzmán MG.

Arch Virol. 2014 Oct;159(10):2597-604. doi: 10.1007/s00705-014-2115-2. Epub 2014 May 20.

PMID:
24841761
16.

Protection against dengue virus by non-replicating and live attenuated vaccines used together in a prime boost vaccination strategy.

Simmons M, Burgess T, Lynch J, Putnak R.

Virology. 2010 Jan 20;396(2):280-8. doi: 10.1016/j.virol.2009.10.023. Epub 2009 Nov 13.

17.

Evaluation of interferences between dengue vaccine serotypes in a monkey model.

Guy B, Barban V, Mantel N, Aguirre M, Gulia S, Pontvianne J, Jourdier TM, Ramirez L, Gregoire V, Charnay C, Burdin N, Dumas R, Lang J.

Am J Trop Med Hyg. 2009 Feb;80(2):302-11.

PMID:
19190230
18.

Pediatric measles vaccine expressing a dengue tetravalent antigen elicits neutralizing antibodies against all four dengue viruses.

Brandler S, Ruffie C, Najburg V, Frenkiel MP, Bedouelle H, Desprès P, Tangy F.

Vaccine. 2010 Sep 24;28(41):6730-9. doi: 10.1016/j.vaccine.2010.07.073. Epub 2010 Aug 3.

PMID:
20688034
19.

Viremia and immunogenicity in nonhuman primates of a tetravalent yellow fever-dengue chimeric vaccine: genetic reconstructions, dose adjustment, and antibody responses against wild-type dengue virus isolates.

Guirakhoo F, Pugachev K, Arroyo J, Miller C, Zhang ZX, Weltzin R, Georgakopoulos K, Catalan J, Ocran S, Draper K, Monath TP.

Virology. 2002 Jun 20;298(1):146-59.

20.

Capsid protein: evidences about the partial protective role of neutralizing antibody-independent immunity against dengue in monkeys.

Gil L, Izquierdo A, Lazo L, Valdés I, Ambala P, Ochola L, Marcos E, Suzarte E, Kariuki T, Guzmán G, Guillén G, Hermida L.

Virology. 2014 May;456-457:70-6. doi: 10.1016/j.virol.2014.03.011. Epub 2014 Mar 29.

Supplemental Content

Support Center